nodes	percent_of_prediction	percent_of_DWPC	metapath
Ropinirole—Vitamin B12 deficiency—Metformin—polycystic ovary syndrome	0.0388	0.117	CcSEcCtD
Ropinirole—Angina unstable—Metformin—polycystic ovary syndrome	0.0161	0.0485	CcSEcCtD
Ropinirole—Tonsillitis—Metformin—polycystic ovary syndrome	0.0161	0.0485	CcSEcCtD
Ropinirole—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.0156	0.0469	CcSEcCtD
Ropinirole—Sinus headache—Metformin—polycystic ovary syndrome	0.0125	0.0376	CcSEcCtD
Ropinirole—Tooth abscess—Metformin—polycystic ovary syndrome	0.00975	0.0293	CcSEcCtD
Ropinirole—Sinus congestion—Metformin—polycystic ovary syndrome	0.00818	0.0246	CcSEcCtD
Ropinirole—Azotaemia—Metformin—polycystic ovary syndrome	0.00764	0.023	CcSEcCtD
Ropinirole—Acidosis—Metformin—polycystic ovary syndrome	0.00736	0.0221	CcSEcCtD
Ropinirole—Loose stools—Metformin—polycystic ovary syndrome	0.00736	0.0221	CcSEcCtD
Ropinirole—Toothache—Metformin—polycystic ovary syndrome	0.00669	0.0201	CcSEcCtD
Ropinirole—Nail disorder—Metformin—polycystic ovary syndrome	0.00628	0.0189	CcSEcCtD
Ropinirole—Upset stomach—Metformin—polycystic ovary syndrome	0.00622	0.0187	CcSEcCtD
Ropinirole—CYP1A2—urine—polycystic ovary syndrome	0.00569	0.0833	CbGeAlD
Ropinirole—Fungal infection—Metformin—polycystic ovary syndrome	0.00527	0.0159	CcSEcCtD
Ropinirole—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00503	0.0151	CcSEcCtD
Ropinirole—Rigors—Metformin—polycystic ovary syndrome	0.00499	0.015	CcSEcCtD
Ropinirole—Blood disorder—Metformin—polycystic ovary syndrome	0.00488	0.0147	CcSEcCtD
Ropinirole—Chest discomfort—Metformin—polycystic ovary syndrome	0.0046	0.0138	CcSEcCtD
Ropinirole—HTR2A—urine—polycystic ovary syndrome	0.00445	0.0652	CbGeAlD
Ropinirole—CYP3A4—urine—polycystic ovary syndrome	0.00412	0.0603	CbGeAlD
Ropinirole—CYP2D6—urine—polycystic ovary syndrome	0.00406	0.0594	CbGeAlD
Ropinirole—Neuropathy—Metformin—polycystic ovary syndrome	0.00382	0.0115	CcSEcCtD
Ropinirole—Ear pain—Metformin—polycystic ovary syndrome	0.00346	0.0104	CcSEcCtD
Ropinirole—Nasal congestion—Metformin—polycystic ovary syndrome	0.00325	0.00976	CcSEcCtD
Ropinirole—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00303	0.00911	CcSEcCtD
Ropinirole—Lethargy—Metformin—polycystic ovary syndrome	0.00302	0.00907	CcSEcCtD
Ropinirole—Pain in extremity—Metformin—polycystic ovary syndrome	0.00296	0.00889	CcSEcCtD
Ropinirole—Migraine—Metformin—polycystic ovary syndrome	0.00291	0.00875	CcSEcCtD
Ropinirole—Dehydration—Metformin—polycystic ovary syndrome	0.00275	0.00827	CcSEcCtD
Ropinirole—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.0027	0.00812	CcSEcCtD
Ropinirole—Breast disorder—Metformin—polycystic ovary syndrome	0.00267	0.00804	CcSEcCtD
Ropinirole—DRD5—female gonad—polycystic ovary syndrome	0.00267	0.039	CbGeAlD
Ropinirole—Cramp muscle—Metformin—polycystic ovary syndrome	0.00266	0.00801	CcSEcCtD
Ropinirole—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00264	0.00795	CcSEcCtD
Ropinirole—Abdominal distension—Metformin—polycystic ovary syndrome	0.00257	0.00774	CcSEcCtD
Ropinirole—Influenza—Metformin—polycystic ovary syndrome	0.00256	0.00769	CcSEcCtD
Ropinirole—Pancreatitis—Metformin—polycystic ovary syndrome	0.00251	0.00754	CcSEcCtD
Ropinirole—Angina pectoris—Metformin—polycystic ovary syndrome	0.00249	0.00749	CcSEcCtD
Ropinirole—Sweating increased—Metformin—polycystic ovary syndrome	0.00249	0.00749	CcSEcCtD
Ropinirole—DRD5—endocrine gland—polycystic ovary syndrome	0.00248	0.0363	CbGeAlD
Ropinirole—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00245	0.00737	CcSEcCtD
Ropinirole—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00237	0.00714	CcSEcCtD
Ropinirole—Infestation NOS—Metformin—polycystic ovary syndrome	0.00228	0.00685	CcSEcCtD
Ropinirole—Infestation—Metformin—polycystic ovary syndrome	0.00228	0.00685	CcSEcCtD
Ropinirole—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00223	0.00672	CcSEcCtD
Ropinirole—HTR2B—adrenal cortex—polycystic ovary syndrome	0.00221	0.0323	CbGeAlD
Ropinirole—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00215	0.00648	CcSEcCtD
Ropinirole—Bradycardia—Metformin—polycystic ovary syndrome	0.00208	0.00626	CcSEcCtD
Ropinirole—Rhinitis—Metformin—polycystic ovary syndrome	0.00205	0.00617	CcSEcCtD
Ropinirole—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00203	0.00612	CcSEcCtD
Ropinirole—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00201	0.00606	CcSEcCtD
Ropinirole—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00201	0.00605	CcSEcCtD
Ropinirole—HTR2B—endometrium—polycystic ovary syndrome	0.00197	0.0289	CbGeAlD
Ropinirole—Eye disorder—Metformin—polycystic ovary syndrome	0.00191	0.00575	CcSEcCtD
Ropinirole—Flushing—Metformin—polycystic ovary syndrome	0.0019	0.00571	CcSEcCtD
Ropinirole—Cardiac disorder—Metformin—polycystic ovary syndrome	0.0019	0.00571	CcSEcCtD
Ropinirole—Angiopathy—Metformin—polycystic ovary syndrome	0.00186	0.00558	CcSEcCtD
Ropinirole—Immune system disorder—Metformin—polycystic ovary syndrome	0.00185	0.00556	CcSEcCtD
Ropinirole—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00184	0.00554	CcSEcCtD
Ropinirole—Chills—Metformin—polycystic ovary syndrome	0.00184	0.00552	CcSEcCtD
Ropinirole—HTR2B—uterus—polycystic ovary syndrome	0.00182	0.0266	CbGeAlD
Ropinirole—Malnutrition—Metformin—polycystic ovary syndrome	0.00178	0.00536	CcSEcCtD
Ropinirole—HTR2B—adipose tissue—polycystic ovary syndrome	0.00178	0.026	CbGeAlD
Ropinirole—Flatulence—Metformin—polycystic ovary syndrome	0.00175	0.00528	CcSEcCtD
Ropinirole—Dysgeusia—Metformin—polycystic ovary syndrome	0.00174	0.00524	CcSEcCtD
Ropinirole—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.00174	0.0254	CbGeAlD
Ropinirole—Muscle spasms—Metformin—polycystic ovary syndrome	0.00171	0.00515	CcSEcCtD
Ropinirole—Vision blurred—Metformin—polycystic ovary syndrome	0.00168	0.00505	CcSEcCtD
Ropinirole—Tremor—Metformin—polycystic ovary syndrome	0.00167	0.00502	CcSEcCtD
Ropinirole—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00165	0.00497	CcSEcCtD
Ropinirole—Malaise—Metformin—polycystic ovary syndrome	0.00161	0.00483	CcSEcCtD
Ropinirole—Syncope—Metformin—polycystic ovary syndrome	0.0016	0.0048	CcSEcCtD
Ropinirole—HTR2B—adrenal gland—polycystic ovary syndrome	0.00159	0.0233	CbGeAlD
Ropinirole—Palpitations—Metformin—polycystic ovary syndrome	0.00157	0.00473	CcSEcCtD
Ropinirole—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00156	0.00471	CcSEcCtD
Ropinirole—ADRA2C—endometrium—polycystic ovary syndrome	0.00155	0.0227	CbGeAlD
Ropinirole—Hypertension—Metformin—polycystic ovary syndrome	0.00154	0.00462	CcSEcCtD
Ropinirole—HTR1B—endocrine gland—polycystic ovary syndrome	0.00153	0.0225	CbGeAlD
Ropinirole—Myalgia—Metformin—polycystic ovary syndrome	0.00152	0.00456	CcSEcCtD
Ropinirole—Chest pain—Metformin—polycystic ovary syndrome	0.00152	0.00456	CcSEcCtD
Ropinirole—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00151	0.00453	CcSEcCtD
Ropinirole—Discomfort—Metformin—polycystic ovary syndrome	0.0015	0.0045	CcSEcCtD
Ropinirole—HTR2B—vagina—polycystic ovary syndrome	0.00148	0.0216	CbGeAlD
Ropinirole—Oedema—Metformin—polycystic ovary syndrome	0.00145	0.00437	CcSEcCtD
Ropinirole—DRD2—pituitary gland—polycystic ovary syndrome	0.00144	0.0211	CbGeAlD
Ropinirole—Infection—Metformin—polycystic ovary syndrome	0.00144	0.00434	CcSEcCtD
Ropinirole—HTR2A—embryo—polycystic ovary syndrome	0.00144	0.0211	CbGeAlD
Ropinirole—ADRA2C—uterus—polycystic ovary syndrome	0.00143	0.0209	CbGeAlD
Ropinirole—Shock—Metformin—polycystic ovary syndrome	0.00143	0.0043	CcSEcCtD
Ropinirole—HTR1A—adrenal gland—polycystic ovary syndrome	0.00143	0.0209	CbGeAlD
Ropinirole—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00142	0.00429	CcSEcCtD
Ropinirole—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00142	0.00428	CcSEcCtD
Ropinirole—Skin disorder—Metformin—polycystic ovary syndrome	0.00141	0.00425	CcSEcCtD
Ropinirole—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.0014	0.00423	CcSEcCtD
Ropinirole—ADRA2C—pituitary gland—polycystic ovary syndrome	0.0014	0.0206	CbGeAlD
Ropinirole—ADRA2C—adipose tissue—polycystic ovary syndrome	0.0014	0.0205	CbGeAlD
Ropinirole—Anorexia—Metformin—polycystic ovary syndrome	0.00138	0.00417	CcSEcCtD
Ropinirole—Hypotension—Metformin—polycystic ovary syndrome	0.00136	0.00408	CcSEcCtD
Ropinirole—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00132	0.00398	CcSEcCtD
Ropinirole—Paraesthesia—Metformin—polycystic ovary syndrome	0.0013	0.00392	CcSEcCtD
Ropinirole—Dyspnoea—Metformin—polycystic ovary syndrome	0.0013	0.0039	CcSEcCtD
Ropinirole—Somnolence—Metformin—polycystic ovary syndrome	0.00129	0.00389	CcSEcCtD
Ropinirole—Dyspepsia—Metformin—polycystic ovary syndrome	0.00128	0.00385	CcSEcCtD
Ropinirole—Decreased appetite—Metformin—polycystic ovary syndrome	0.00126	0.0038	CcSEcCtD
Ropinirole—ADRA2C—adrenal gland—polycystic ovary syndrome	0.00125	0.0184	CbGeAlD
Ropinirole—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00125	0.00377	CcSEcCtD
Ropinirole—Fatigue—Metformin—polycystic ovary syndrome	0.00125	0.00377	CcSEcCtD
Ropinirole—Constipation—Metformin—polycystic ovary syndrome	0.00124	0.00374	CcSEcCtD
Ropinirole—HTR1A—endocrine gland—polycystic ovary syndrome	0.00124	0.0181	CbGeAlD
Ropinirole—ADRA2A—endometrium—polycystic ovary syndrome	0.00124	0.0181	CbGeAlD
Ropinirole—Feeling abnormal—Metformin—polycystic ovary syndrome	0.0012	0.0036	CcSEcCtD
Ropinirole—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00119	0.00357	CcSEcCtD
Ropinirole—ADRA2C—female gonad—polycystic ovary syndrome	0.00117	0.0171	CbGeAlD
Ropinirole—ADRA2C—vagina—polycystic ovary syndrome	0.00116	0.017	CbGeAlD
Ropinirole—Urticaria—Metformin—polycystic ovary syndrome	0.00115	0.00347	CcSEcCtD
Ropinirole—Abdominal pain—Metformin—polycystic ovary syndrome	0.00115	0.00346	CcSEcCtD
Ropinirole—ADRA2A—uterus—polycystic ovary syndrome	0.00114	0.0167	CbGeAlD
Ropinirole—ADRA2A—pituitary gland—polycystic ovary syndrome	0.00112	0.0164	CbGeAlD
Ropinirole—DRD2—endocrine gland—polycystic ovary syndrome	0.00112	0.0164	CbGeAlD
Ropinirole—ADRA2A—adipose tissue—polycystic ovary syndrome	0.00112	0.0163	CbGeAlD
Ropinirole—Asthenia—Metformin—polycystic ovary syndrome	0.00104	0.00314	CcSEcCtD
Ropinirole—Pruritus—Metformin—polycystic ovary syndrome	0.00103	0.00309	CcSEcCtD
Ropinirole—ADRA2A—adrenal gland—polycystic ovary syndrome	0.001	0.0147	CbGeAlD
Ropinirole—Diarrhoea—Metformin—polycystic ovary syndrome	0.000994	0.00299	CcSEcCtD
Ropinirole—Dizziness—Metformin—polycystic ovary syndrome	0.000961	0.00289	CcSEcCtD
Ropinirole—HTR2A—pituitary gland—polycystic ovary syndrome	0.000953	0.0139	CbGeAlD
Ropinirole—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000944	0.0138	CbGeAlD
Ropinirole—ADRA2A—female gonad—polycystic ovary syndrome	0.000933	0.0137	CbGeAlD
Ropinirole—ADRA2A—vagina—polycystic ovary syndrome	0.000928	0.0136	CbGeAlD
Ropinirole—Vomiting—Metformin—polycystic ovary syndrome	0.000924	0.00278	CcSEcCtD
Ropinirole—Rash—Metformin—polycystic ovary syndrome	0.000916	0.00276	CcSEcCtD
Ropinirole—Dermatitis—Metformin—polycystic ovary syndrome	0.000915	0.00275	CcSEcCtD
Ropinirole—Headache—Metformin—polycystic ovary syndrome	0.00091	0.00274	CcSEcCtD
Ropinirole—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000868	0.0127	CbGeAlD
Ropinirole—Nausea—Metformin—polycystic ovary syndrome	0.000863	0.0026	CcSEcCtD
Ropinirole—HTR2A—adrenal gland—polycystic ovary syndrome	0.000851	0.0125	CbGeAlD
Ropinirole—HTR2A—vagina—polycystic ovary syndrome	0.000789	0.0115	CbGeAlD
Ropinirole—HTR2A—endocrine gland—polycystic ovary syndrome	0.000738	0.0108	CbGeAlD
Ropinirole—CYP2D6—female gonad—polycystic ovary syndrome	0.000723	0.0106	CbGeAlD
Ropinirole—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000683	0.01	CbGeAlD
Ropinirole—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000672	0.00984	CbGeAlD
Ropinirole—DRD4—Signaling Pathways—LEP—polycystic ovary syndrome	2.42e-05	4.04e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—NGFR—polycystic ovary syndrome	2.41e-05	4.02e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	2.39e-05	4e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling by GPCR—POMC—polycystic ovary syndrome	2.39e-05	4e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—GNAS—polycystic ovary syndrome	2.39e-05	3.99e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—PRL—polycystic ovary syndrome	2.39e-05	3.98e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—GNAS—polycystic ovary syndrome	2.38e-05	3.97e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—NGFR—polycystic ovary syndrome	2.37e-05	3.96e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—IRS2—polycystic ovary syndrome	2.36e-05	3.94e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.36e-05	3.94e-05	CbGpPWpGaD
Ropinirole—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.36e-05	3.94e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling by GPCR—POMC—polycystic ovary syndrome	2.36e-05	3.93e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	2.35e-05	3.92e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—PRL—polycystic ovary syndrome	2.35e-05	3.92e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	2.35e-05	3.92e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	2.34e-05	3.9e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Metabolism—MTHFR—polycystic ovary syndrome	2.33e-05	3.89e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	2.32e-05	3.87e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—NRG1—polycystic ovary syndrome	2.32e-05	3.87e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—GNAS—polycystic ovary syndrome	2.31e-05	3.86e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—LEP—polycystic ovary syndrome	2.31e-05	3.86e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.3e-05	3.84e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.28e-05	3.8e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.28e-05	3.8e-05	CbGpPWpGaD
Ropinirole—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.27e-05	3.79e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.27e-05	3.78e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.27e-05	3.78e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.26e-05	3.78e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	2.26e-05	3.77e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	2.25e-05	3.75e-05	CbGpPWpGaD
Ropinirole—HTR1D—Signaling Pathways—IRS1—polycystic ovary syndrome	2.24e-05	3.74e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—NRG1—polycystic ovary syndrome	2.24e-05	3.73e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	2.23e-05	3.72e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.23e-05	3.72e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—IRS2—polycystic ovary syndrome	2.23e-05	3.72e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—NRG1—polycystic ovary syndrome	2.23e-05	3.71e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.21e-05	3.68e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—IRS2—polycystic ovary syndrome	2.2e-05	3.67e-05	CbGpPWpGaD
Ropinirole—HTR1B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.2e-05	3.66e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—LEP—polycystic ovary syndrome	2.18e-05	3.64e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	2.17e-05	3.63e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	2.16e-05	3.61e-05	CbGpPWpGaD
Ropinirole—DRD4—Signaling Pathways—IRS1—polycystic ovary syndrome	2.16e-05	3.61e-05	CbGpPWpGaD
Ropinirole—HTR1D—Signaling Pathways—POMC—polycystic ovary syndrome	2.16e-05	3.6e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	2.16e-05	3.6e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—LEP—polycystic ovary syndrome	2.15e-05	3.59e-05	CbGpPWpGaD
Ropinirole—HTR1D—Signaling Pathways—INS—polycystic ovary syndrome	2.15e-05	3.58e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	2.14e-05	3.58e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	2.14e-05	3.57e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	2.14e-05	3.57e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	2.13e-05	3.56e-05	CbGpPWpGaD
Ropinirole—HTR1B—Signaling Pathways—POMC—polycystic ovary syndrome	2.11e-05	3.53e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	2.11e-05	3.52e-05	CbGpPWpGaD
Ropinirole—HTR1B—Signaling Pathways—INS—polycystic ovary syndrome	2.1e-05	3.51e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	2.1e-05	3.51e-05	CbGpPWpGaD
Ropinirole—DRD4—Signaling Pathways—POMC—polycystic ovary syndrome	2.08e-05	3.47e-05	CbGpPWpGaD
Ropinirole—HTR1D—Signaling Pathways—IGF1—polycystic ovary syndrome	2.08e-05	3.47e-05	CbGpPWpGaD
Ropinirole—HTR1D—Signaling Pathways—AKT2—polycystic ovary syndrome	2.08e-05	3.46e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	2.07e-05	3.46e-05	CbGpPWpGaD
Ropinirole—DRD5—Signaling by GPCR—IL6—polycystic ovary syndrome	2.07e-05	3.46e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	2.07e-05	3.46e-05	CbGpPWpGaD
Ropinirole—DRD4—Signaling Pathways—INS—polycystic ovary syndrome	2.07e-05	3.45e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	2.07e-05	3.45e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	2.07e-05	3.45e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.06e-05	3.44e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.06e-05	3.44e-05	CbGpPWpGaD
Ropinirole—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.03e-05	3.39e-05	CbGpPWpGaD
Ropinirole—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.03e-05	3.39e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	2.03e-05	3.39e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.03e-05	3.38e-05	CbGpPWpGaD
Ropinirole—DRD4—Signaling Pathways—IGF1—polycystic ovary syndrome	2e-05	3.34e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	2e-05	3.34e-05	CbGpPWpGaD
Ropinirole—DRD4—Signaling Pathways—AKT2—polycystic ovary syndrome	2e-05	3.34e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	1.99e-05	3.32e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—POMC—polycystic ovary syndrome	1.99e-05	3.31e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.98e-05	3.31e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—INS—polycystic ovary syndrome	1.98e-05	3.3e-05	CbGpPWpGaD
Ropinirole—HTR1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.97e-05	3.29e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.97e-05	3.29e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.96e-05	3.28e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.95e-05	3.25e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	1.94e-05	3.24e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.93e-05	3.22e-05	CbGpPWpGaD
Ropinirole—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.93e-05	3.22e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.92e-05	3.2e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.92e-05	3.2e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	1.91e-05	3.19e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.91e-05	3.19e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.91e-05	3.19e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	1.91e-05	3.18e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.9e-05	3.18e-05	CbGpPWpGaD
Ropinirole—DRD4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.9e-05	3.17e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	1.89e-05	3.16e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	1.89e-05	3.15e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	1.89e-05	3.15e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	1.89e-05	3.15e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.88e-05	3.14e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.88e-05	3.13e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	1.88e-05	3.13e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—POMC—polycystic ovary syndrome	1.87e-05	3.13e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	1.87e-05	3.11e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	1.86e-05	3.11e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—INS—polycystic ovary syndrome	1.86e-05	3.11e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	1.85e-05	3.09e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Metabolism—INS—polycystic ovary syndrome	1.85e-05	3.09e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—POMC—polycystic ovary syndrome	1.85e-05	3.08e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	1.85e-05	3.08e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—INS—polycystic ovary syndrome	1.84e-05	3.07e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	1.81e-05	3.03e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.81e-05	3.03e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.8e-05	3.01e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.8e-05	3e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—TH—polycystic ovary syndrome	1.79e-05	3e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.79e-05	2.99e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.79e-05	2.99e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	1.79e-05	2.98e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—IGF1—polycystic ovary syndrome	1.78e-05	2.97e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—AKT2—polycystic ovary syndrome	1.78e-05	2.96e-05	CbGpPWpGaD
Ropinirole—DRD5—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.77e-05	2.96e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.76e-05	2.93e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	1.76e-05	2.93e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	1.75e-05	2.91e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.73e-05	2.89e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.71e-05	2.86e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.69e-05	2.82e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.68e-05	2.81e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.67e-05	2.79e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	1.67e-05	2.78e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	1.66e-05	2.78e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	1.66e-05	2.77e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.66e-05	2.76e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.65e-05	2.75e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	1.65e-05	2.75e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	1.64e-05	2.74e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	1.62e-05	2.7e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	1.62e-05	2.7e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	1.61e-05	2.69e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.61e-05	2.68e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.6e-05	2.68e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	1.6e-05	2.67e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	1.6e-05	2.67e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.6e-05	2.66e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	1.59e-05	2.66e-05	CbGpPWpGaD
Ropinirole—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	1.59e-05	2.65e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	1.56e-05	2.6e-05	CbGpPWpGaD
Ropinirole—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.56e-05	2.6e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	1.55e-05	2.59e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	1.55e-05	2.59e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.55e-05	2.58e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	1.54e-05	2.57e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	1.54e-05	2.57e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.54e-05	2.57e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	1.54e-05	2.56e-05	CbGpPWpGaD
Ropinirole—DRD4—Signaling by GPCR—IL6—polycystic ovary syndrome	1.53e-05	2.55e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.52e-05	2.54e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—TH—polycystic ovary syndrome	1.52e-05	2.54e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	1.51e-05	2.53e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.51e-05	2.51e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Metabolism—INS—polycystic ovary syndrome	1.51e-05	2.51e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	1.5e-05	2.5e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	1.5e-05	2.5e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	1.48e-05	2.47e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.48e-05	2.47e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	1.47e-05	2.46e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.47e-05	2.46e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.47e-05	2.45e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	1.47e-05	2.45e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.46e-05	2.44e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.46e-05	2.44e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.46e-05	2.43e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.45e-05	2.41e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.42e-05	2.38e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	1.41e-05	2.36e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	1.41e-05	2.35e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	1.4e-05	2.33e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	1.39e-05	2.32e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	1.39e-05	2.32e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	1.38e-05	2.31e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.38e-05	2.3e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.38e-05	2.3e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.36e-05	2.27e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling by GPCR—IL6—polycystic ovary syndrome	1.36e-05	2.27e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.36e-05	2.27e-05	CbGpPWpGaD
Ropinirole—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.36e-05	2.26e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.36e-05	2.26e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	1.34e-05	2.23e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.34e-05	2.23e-05	CbGpPWpGaD
Ropinirole—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.33e-05	2.22e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	1.32e-05	2.21e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.31e-05	2.19e-05	CbGpPWpGaD
Ropinirole—DRD4—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.31e-05	2.18e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.29e-05	2.16e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.27e-05	2.12e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	1.27e-05	2.11e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	1.26e-05	2.1e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.25e-05	2.08e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	1.24e-05	2.07e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	1.23e-05	2.06e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.23e-05	2.05e-05	CbGpPWpGaD
Ropinirole—DRD5—Signaling Pathways—IL6—polycystic ovary syndrome	1.23e-05	2.04e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	1.22e-05	2.03e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.22e-05	2.03e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.18e-05	1.98e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	1.18e-05	1.97e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	1.18e-05	1.97e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.18e-05	1.96e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.17e-05	1.96e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.16e-05	1.94e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.16e-05	1.93e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	1.15e-05	1.91e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.14e-05	1.9e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.12e-05	1.87e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.07e-05	1.79e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.05e-05	1.75e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.05e-05	1.74e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.04e-05	1.74e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.02e-05	1.71e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.01e-05	1.69e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.01e-05	1.68e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	1e-05	1.67e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	9.87e-06	1.65e-05	CbGpPWpGaD
Ropinirole—CYP2D6—Metabolism—INS—polycystic ovary syndrome	9.81e-06	1.64e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.79e-06	1.63e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	9.58e-06	1.6e-05	CbGpPWpGaD
Ropinirole—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	9.38e-06	1.57e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	9.31e-06	1.55e-05	CbGpPWpGaD
Ropinirole—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	9.19e-06	1.53e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	9.13e-06	1.52e-05	CbGpPWpGaD
Ropinirole—DRD4—Signaling Pathways—IL6—polycystic ovary syndrome	9.04e-06	1.51e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.89e-06	1.48e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.74e-06	1.46e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	8.65e-06	1.44e-05	CbGpPWpGaD
Ropinirole—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	8.63e-06	1.44e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	8.47e-06	1.41e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	8.36e-06	1.39e-05	CbGpPWpGaD
Ropinirole—CYP1A2—Metabolism—INS—polycystic ovary syndrome	8.31e-06	1.39e-05	CbGpPWpGaD
Ropinirole—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	8.14e-06	1.36e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	8.07e-06	1.35e-05	CbGpPWpGaD
Ropinirole—DRD3—Signaling Pathways—IL6—polycystic ovary syndrome	8.03e-06	1.34e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.95e-06	1.33e-05	CbGpPWpGaD
Ropinirole—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	7.25e-06	1.21e-05	CbGpPWpGaD
Ropinirole—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	7e-06	1.17e-05	CbGpPWpGaD
Ropinirole—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	6.96e-06	1.16e-05	CbGpPWpGaD
Ropinirole—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	6.77e-06	1.13e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	6.54e-06	1.09e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	6.45e-06	1.08e-05	CbGpPWpGaD
Ropinirole—CYP3A4—Metabolism—INS—polycystic ovary syndrome	6.41e-06	1.07e-05	CbGpPWpGaD
Ropinirole—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	6.15e-06	1.03e-05	CbGpPWpGaD
Ropinirole—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	6.05e-06	1.01e-05	CbGpPWpGaD
Ropinirole—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	5.5e-06	9.18e-06	CbGpPWpGaD
